Zalicus and Epirus announce merger agreement
Zalicus and Epirus Biopharmaceuticals announced an agreement whereby Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. Zalicus will be re-named Epirus Biopharmaceuticals, Inc., and will operate under the leadership of the Epirus management. April 16, 2014